About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
The University of Kansas Cancer Center
https://www.kucancercenter.org/
2023 Multidisciplinary Oncology Review
2022
Advances in Hematologic Malignancies and Cellular Therapeutics Symposium
2022 Post San Antonio Review
Videos
2021
2021 Virtual KU Hematology and Medical Oncology Review
2021 Post San Antonio Review
2021 KUMC Virtual Multidisciplinary Oncology Review
2020
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
2020 ASCO Highlights
2019
2019 Post San Antonio Breast Cancer Review
ASH 2019 Review: Current Updates in Hematologic Diseases
2019 Lung Cancer and Head & Neck Cancer Symposium
Hematology & Medical Oncology Review 2019
Lung
Hematologic Malignancies
Gastrointestinal
Head and Neck
Genitourinary
Skin
Palliative
General
Event
2018
ASH: Current Updates in Hematologic Diseases
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
ASH December 2018 - MRD in AML - What is the Benefit / Risk Ratio Related to HCT?
By
KU ASH 2018 Review: Current Updates in Hematologic Diseases
FEATURING
Elihu H. Estey
By
KU ASH 2018 Review: Current Updates in Hematologic Diseases
FEATURING
Elihu H. Estey
191 views
March 19, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
ASH: Current Updates in Hematologic Diseases
22:39
KU ASH 2018 Review: Current Updates in Hematologic Diseases
ASH December 2018 - MDS - Top Trials and Key Takeaways
Feat.
B. Skikne
25:14
KU ASH 2018 Review: Current Updates in Hematologic Diseases
ASH December 2018 - MPN - Review and Synthesis of Recent Trials
Feat.
A. Yacoub
26:11
KU ASH 2018 Review: Current Updates in Hematologic Diseases
ASH 2018 Myeloid Neoplasms - How Recent Trials on Stem Cell Transpla…
Feat.
A. Singh
28:21
KU ASH 2018 Review: Current Updates in Hematologic Diseases
ASH December 2018 - Benign Hematolgy - Analysis of Top Trials
Feat.
P. Harris
30:39
KU ASH 2018 Review: Current Updates in Hematologic Diseases
ASH December 2018 - CLL and Indolent Lymphoma - Review of Clinical T…
Feat.
M. Hoffmann
21:22
KU ASH 2018 Review: Current Updates in Hematologic Diseases
ASH December 2018- Aggressive Lymphomas: Recent Approvals and Promis…
Feat.
A. Vallurupalli
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases
MM - Overview of Trials Presented at ASH 2018
Feat.
A. Abdallah
06:55
KU ASH 2018 Review: Current Updates in Hematologic Diseases
ASH December 2018 - Lymphoma- Historical Perspective of CAR-T Cell T…
Feat.
F. Locke
24:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases
ASH December 2018- Lymphoma - Efficacy and Safety from ZUMA 1, JULIE…
Feat.
F. Locke
14:52
KU ASH 2018 Review: Current Updates in Hematologic Diseases
ASH December 2018 - Lymphoma - Axi-cel as Standard of Care and Relat…
Feat.
F. Locke
03:50
KU ASH 2018 Review: Current Updates in Hematologic Diseases
ASH December 2018 - Myeloma - BCMA CAR T Therapy for Refractory Pati…
Feat.
F. Locke
23:37
KU ASH 2018 Review: Current Updates in Hematologic Diseases
ASH 2018 AML: Deciding Between Standard vs Investigational Therapies…
Feat.
E. Estey
05:54
KU ASH 2018 Review: Current Updates in Hematologic Diseases
ASH December 2018 - MRD in AML - What is the Benefit / Risk Ratio Re…
Feat.
E. Estey
06:26
KU ASH 2018 Review: Current Updates in Hematologic Diseases
ASH December 2018 - AML - Allogeneic Hematopoietic Cell Transplantat…
Feat.
E. Estey
14:49
KU ASH 2018 Review: Current Updates in Hematologic Diseases
ASH 2018 AML Challenges in Evaluating New Therapies: Understanding t…
Feat.
E. Estey
06:55
KU ASH 2018 Review: Current Updates in Hematologic Diseases
Lymphoma and Myeloma - Cellular Therapy, Efficacy and Safety from Top Tria…
Feat.
F. Locke
